Dr. Camille Granvil, Ph.D

Dr. Camille Granvil is a clinical pharmacologist with over 24 years of global experience in drug development, primarily in oncology, with additional exposure in virology and ophthalmology. He has contributed to 4 NDA approvals (Aliqopa, Vitrakvi, Odomzo, Besivance), 2 sNDAs (Gleevec, Nilotinib), and numerous INDs across small molecules and biologics. His expertise includes PK/PD modeling, DMPK, pediatric planning, DDI assessment, regulatory strategy, and due diligence.

Dr. Granvil has held senior roles at Gilead, Bayer, Novartis, and Biosplice, and remains an active contributor to ASCPT, AAPS, and ACCP. He earned his PhD and MS in Clinical Pharmacology and BS in Chemistry from the University of Montreal, followed by a postdoctoral fellowship at the NIH.